DBV Technologies reported $394.3M in Market Capitalization this October of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Alnylam Pharmaceuticals USD 22.44B 10.57B Oct/2026
Amarin USD 290M 51M Dec/2025
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
DBV Technologies USD 1.23B 327M Mar/2026
Halozyme Therapeutics USD 9.28B 1.63B Jun/2026
Incyte USD 26.22B 1.63B Oct/2026
Insmed USD 16.56B 8.37B Oct/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
PTC Therapeutics USD 4.94B 1.86B Oct/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
United Therapeutics USD 23B 2.19B Jun/2026